AngioDynamics Competitors

Abbott Laboratories (NYSE:ABT) and AngioDynamics (NASDAQ:ANGO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 92.4% of AngioDynamics shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Comparatively, 3.8% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Abbott Laboratories and AngioDynamics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Abbott Laboratories and AngioDynamics' top-line revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than AngioDynamics. Abbott Laboratories is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Abbott Laboratories and AngioDynamics, as reported by MarketBeat.com.

Abbott Laboratories presently has a consensus target price of $115.3750, indicating a potential upside of 5.59%. AngioDynamics has a consensus target price of $14.00, indicating a potential upside of 11.82%. Given AngioDynamics' higher probable upside, analysts clearly believe AngioDynamics is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats AngioDynamics on 11 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and AngioDynamics (NASDAQ:ANGO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Medtronic and AngioDynamics, as reported by MarketBeat.

Medtronic presently has a consensus price target of $118.1538, indicating a potential upside of 6.47%. AngioDynamics has a consensus price target of $14.00, indicating a potential upside of 11.82%. Given AngioDynamics' higher probable upside, analysts plainly believe AngioDynamics is more favorable than Medtronic.

Insider and Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 92.4% of AngioDynamics shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 3.8% of AngioDynamics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Medtronic and AngioDynamics' gross revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than AngioDynamics. Medtronic is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and AngioDynamics' net margins, return on equity and return on assets.

Volatility & Risk

Medtronic has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Summary

Medtronic beats AngioDynamics on 12 of the 15 factors compared between the two stocks.

AngioDynamics (NASDAQ:ANGO) and Stryker (NYSE:SYK) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Institutional and Insider Ownership

92.4% of AngioDynamics shares are held by institutional investors. Comparatively, 71.0% of Stryker shares are held by institutional investors. 3.8% of AngioDynamics shares are held by insiders. Comparatively, 6.8% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

AngioDynamics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for AngioDynamics and Stryker, as reported by MarketBeat.

AngioDynamics currently has a consensus target price of $14.00, indicating a potential upside of 11.82%. Stryker has a consensus target price of $221.44, indicating a potential downside of 4.97%. Given AngioDynamics' higher possible upside, equities analysts clearly believe AngioDynamics is more favorable than Stryker.

Earnings and Valuation

This table compares AngioDynamics and Stryker's top-line revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than AngioDynamics. Stryker is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AngioDynamics and Stryker's net margins, return on equity and return on assets.

Summary

Stryker beats AngioDynamics on 13 of the 15 factors compared between the two stocks.

AngioDynamics (NASDAQ:ANGO) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk.

Risk and Volatility

AngioDynamics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Valuation and Earnings

This table compares AngioDynamics and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has higher revenue and earnings than AngioDynamics. Intuitive Surgical is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AngioDynamics and Intuitive Surgical's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and target prices for AngioDynamics and Intuitive Surgical, as provided by MarketBeat.com.

AngioDynamics currently has a consensus price target of $14.00, indicating a potential upside of 11.82%. Intuitive Surgical has a consensus price target of $718.2778, indicating a potential downside of 0.11%. Given AngioDynamics' higher possible upside, analysts clearly believe AngioDynamics is more favorable than Intuitive Surgical.

Insider & Institutional Ownership

92.4% of AngioDynamics shares are held by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are held by institutional investors. 3.8% of AngioDynamics shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Intuitive Surgical beats AngioDynamics on 11 of the 14 factors compared between the two stocks.

AngioDynamics (NASDAQ:ANGO) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Earnings & Valuation

This table compares AngioDynamics and Becton, Dickinson and's top-line revenue, earnings per share and valuation.

Becton, Dickinson and has higher revenue and earnings than AngioDynamics. Becton, Dickinson and is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AngioDynamics and Becton, Dickinson and's net margins, return on equity and return on assets.

Volatility and Risk

AngioDynamics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Institutional & Insider Ownership

92.4% of AngioDynamics shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 3.8% of AngioDynamics shares are held by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for AngioDynamics and Becton, Dickinson and, as reported by MarketBeat.com.

AngioDynamics currently has a consensus price target of $14.00, suggesting a potential upside of 11.82%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's stronger consensus rating and higher possible upside, analysts plainly believe Becton, Dickinson and is more favorable than AngioDynamics.

Summary

Becton, Dickinson and beats AngioDynamics on 13 of the 15 factors compared between the two stocks.

AngioDynamics (NASDAQ:ANGO) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for AngioDynamics and Edwards Lifesciences, as provided by MarketBeat.

AngioDynamics currently has a consensus target price of $14.00, indicating a potential upside of 11.82%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given AngioDynamics' higher possible upside, equities analysts clearly believe AngioDynamics is more favorable than Edwards Lifesciences.

Institutional & Insider Ownership

92.4% of AngioDynamics shares are held by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are held by institutional investors. 3.8% of AngioDynamics shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

AngioDynamics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Valuation & Earnings

This table compares AngioDynamics and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Edwards Lifesciences has higher revenue and earnings than AngioDynamics. Edwards Lifesciences is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AngioDynamics and Edwards Lifesciences' net margins, return on equity and return on assets.

Summary

Edwards Lifesciences beats AngioDynamics on 11 of the 14 factors compared between the two stocks.